CD19 and hematologic disorder: As we reflect on the evolution of CAR-T cells over the past 30 years, with 6 CAR-T cell products approved by the FDA between 2017 and 2022, there is substantial anticipation that what we learned from CD19 CAR-T cells provides the foundations for expanding this approach to other hematologic malignancies and eventually to solid tumors.